Type I Collagen:The Dermal Scaffold & Anti-Gravity Agent
Product Focus: Advanced Anti-Aging, Mechanical Lifting, Deep Wrinkle Correction, Dermal Density Restoration.
$200.00 /g
Product Details
Product Description
Detailed Mechanism of Action & Scientific Rationale:
Collagen Type I is the primary structural protein of the human dermis, accounting for approximately 80-90% of the body's total collagen content. In the context of skin aging (chronological and photo-aging), the depletion of Type I collagen leads to the collapse of the extracellular matrix (ECM), resulting in sagging, deep rhytides, and loss of mechanical resilience. Peptide Synbio’s recombinant Type I collagen is engineered to replicate the exact Gly-X-Y amino acid repeat sequence necessary for forming a stable, right-handed triple-helix conformation. This structural integrity is paramount because it allows the molecule to bind specifically to α2β1 integrin receptors located on fibroblast membranes.
Upon binding, our Type I collagen initiates a cascade of mechanotransduction signals within the cell. This process does not merely provide passive "filling"; it actively stimulates the fibroblast's biosynthetic machinery to upregulate the production of endogenous collagen, elastin, and glycosaminoglycans (GAGs). Furthermore, by reinforcing the papillary dermis, it restores the skin’s ability to retain moisture and resist gravitational forces, effectively reversing the hallmarks of senescent skin.
Expanded Functional Characteristics:
>Exceptional Tensile Strength & Structural Support: Unlike globular proteins or hydrolyzed peptides, our high-molecular-weight Type I collagen retains its fibrous nature. It integrates into the existing dermal network to provide immediate tensile strength. This is clinically significant for combating "jowling" and nasolabial fold depth, acting as a bio-scaffold that lifts the skin from within.
>Enhanced Fibroblast Activation & Proliferation: In vitro studies indicate that our recombinant Type I induces a higher rate of fibroblast adhesion and proliferation compared to plant-based alternatives. By activating latent TGF-β (Transforming Growth Factor Beta) complexes sequestered in the ECM, it creates a positive feedback loop for tissue regeneration, counteracting the age-related shift in the Type I to Type III collagen ratio.
>Superior Deep Wrinkle Correction & Volume Restoration: Due to its large molecular size and triple-helix stability, our Type I collagen exhibits excellent residence time within the dermis. It effectively fills the voids left by atrophied fat pads and degraded collagen bundles in the reticular dermis. This results in a visible plumping effect that smooths out severe wrinkles (e.g., marionette lines) rather than just superficially hydrating the epidermis.
>Optimized Bioavailability & Receptor Affinity: Through our proprietary recombinant yeast fermentation process, we eliminate teleopeptides (the terminal ends of the molecule often responsible for antigenicity) while preserving the bioactive sites. This ensures high affinity for human cell receptors, maximizing the biological signal sent to skin cells to "repair" and "rebuild."
>Synergistic Potential with Injectables: Our pharmaceutical-grade raw material is purified to meet the stringent requirements for blending with Hyaluronic Acid (HA) in mesotherapy or injectable dermal fillers. The collagen provides a natural scaffold for the HA, potentially prolonging the filler's longevity and improving tissue integration.
Clinical Efficacy & Performance Metrics:
>Instrumental Measurement: Clinical grading using Cutometer® MPA 580 shows a statistically significant improvement in skin firmness (R0/R2 parameters) and a reduction in sagging surface area within 14-28 days of consistent application.
>Visual Assessment: Expert grader evaluations report a visible decrease in wrinkle depth (measured via PRIMOS Lite imaging) and an improvement in overall skin density and luminosity.
>Long-term Benefits: Continuous use helps prevent the recurrence of deep wrinkles by maintaining a healthy fibroblast environment and protecting against enzymatic degradation by MMPs (Matrix Metalloproteinases).
Primary Applications in Formulations:
>High-Performance Anti-Aging Serums: Concentrated formulas designed to penetrate the stratum corneum and deliver active collagen to the upper dermis.
>Lifting & Firming Creams: Emulsion-based products where Type I collagen reinforces the lipid barrier while providing structural support.
>Post-Procedure Recovery Masks: Used in clinics following ablative laser treatments, microneedling (Collagen Induction Therapy), or chemical peels to accelerate re-epithelialization and reduce downtime.
>Injectable Dermal Fillers (HA+Collagen Blends): As a premium raw material for med-tech companies developing next-generation biostimulatory fillers that offer both immediate volume and long-term collagen neogenesis.
>Neck & Décolleté Treatments: Specialized formulations targeting the thin, fragile skin in these areas prone to "tech neck" lines and crepey texture.
Collagen Type I is the primary structural protein of the human dermis, accounting for approximately 80-90% of the body's total collagen content. In the context of skin aging (chronological and photo-aging), the depletion of Type I collagen leads to the collapse of the extracellular matrix (ECM), resulting in sagging, deep rhytides, and loss of mechanical resilience. Peptide Synbio’s recombinant Type I collagen is engineered to replicate the exact Gly-X-Y amino acid repeat sequence necessary for forming a stable, right-handed triple-helix conformation. This structural integrity is paramount because it allows the molecule to bind specifically to α2β1 integrin receptors located on fibroblast membranes.
Upon binding, our Type I collagen initiates a cascade of mechanotransduction signals within the cell. This process does not merely provide passive "filling"; it actively stimulates the fibroblast's biosynthetic machinery to upregulate the production of endogenous collagen, elastin, and glycosaminoglycans (GAGs). Furthermore, by reinforcing the papillary dermis, it restores the skin’s ability to retain moisture and resist gravitational forces, effectively reversing the hallmarks of senescent skin.
Expanded Functional Characteristics:
>Exceptional Tensile Strength & Structural Support: Unlike globular proteins or hydrolyzed peptides, our high-molecular-weight Type I collagen retains its fibrous nature. It integrates into the existing dermal network to provide immediate tensile strength. This is clinically significant for combating "jowling" and nasolabial fold depth, acting as a bio-scaffold that lifts the skin from within.
>Enhanced Fibroblast Activation & Proliferation: In vitro studies indicate that our recombinant Type I induces a higher rate of fibroblast adhesion and proliferation compared to plant-based alternatives. By activating latent TGF-β (Transforming Growth Factor Beta) complexes sequestered in the ECM, it creates a positive feedback loop for tissue regeneration, counteracting the age-related shift in the Type I to Type III collagen ratio.
>Superior Deep Wrinkle Correction & Volume Restoration: Due to its large molecular size and triple-helix stability, our Type I collagen exhibits excellent residence time within the dermis. It effectively fills the voids left by atrophied fat pads and degraded collagen bundles in the reticular dermis. This results in a visible plumping effect that smooths out severe wrinkles (e.g., marionette lines) rather than just superficially hydrating the epidermis.
>Optimized Bioavailability & Receptor Affinity: Through our proprietary recombinant yeast fermentation process, we eliminate teleopeptides (the terminal ends of the molecule often responsible for antigenicity) while preserving the bioactive sites. This ensures high affinity for human cell receptors, maximizing the biological signal sent to skin cells to "repair" and "rebuild."
>Synergistic Potential with Injectables: Our pharmaceutical-grade raw material is purified to meet the stringent requirements for blending with Hyaluronic Acid (HA) in mesotherapy or injectable dermal fillers. The collagen provides a natural scaffold for the HA, potentially prolonging the filler's longevity and improving tissue integration.
Clinical Efficacy & Performance Metrics:
>Instrumental Measurement: Clinical grading using Cutometer® MPA 580 shows a statistically significant improvement in skin firmness (R0/R2 parameters) and a reduction in sagging surface area within 14-28 days of consistent application.
>Visual Assessment: Expert grader evaluations report a visible decrease in wrinkle depth (measured via PRIMOS Lite imaging) and an improvement in overall skin density and luminosity.
>Long-term Benefits: Continuous use helps prevent the recurrence of deep wrinkles by maintaining a healthy fibroblast environment and protecting against enzymatic degradation by MMPs (Matrix Metalloproteinases).
Primary Applications in Formulations:
>High-Performance Anti-Aging Serums: Concentrated formulas designed to penetrate the stratum corneum and deliver active collagen to the upper dermis.
>Lifting & Firming Creams: Emulsion-based products where Type I collagen reinforces the lipid barrier while providing structural support.
>Post-Procedure Recovery Masks: Used in clinics following ablative laser treatments, microneedling (Collagen Induction Therapy), or chemical peels to accelerate re-epithelialization and reduce downtime.
>Injectable Dermal Fillers (HA+Collagen Blends): As a premium raw material for med-tech companies developing next-generation biostimulatory fillers that offer both immediate volume and long-term collagen neogenesis.
>Neck & Décolleté Treatments: Specialized formulations targeting the thin, fragile skin in these areas prone to "tech neck" lines and crepey texture.